<DOC>
	<DOCNO>NCT02888470</DOCNO>
	<brief_summary>The aim study estimate proportion intensive care unit patient receive current aminoglycosides dose regimen part antibiotic therapy achieve recommend maximal plasma concentration ( Cmax ) first subsequent aminoglycoside dos .</brief_summary>
	<brief_title>Administration Amino-glycoside ICU Patients : Clinical Practices 2013</brief_title>
	<detailed_description>Aminoglycosides often prescribed part empirical therapy severe sepsis septic shock , especially Gram-negative bacteria suspect . From pharmacodynamic perspective , ratio maximal plasma concentration ( Cmax ) minimum inhibitory concentration ( MIC ) infect pathogen ( Cmax/MIC ) consider best index bacterial kill aminoglycosides . In 2011 , French guideline aminoglycoside use recommend target Cmax 30-40 mg/L gentamicin 60-80 mg/L amikacin . However , recommend plasma level may achieve high risk patient ICU patient . Many factor influence pharmacokinetics antimicrobial drug critically ill patient . Indeed , alteration volume distribution , plasma albumin concentration , increase cardiac output , increase blood volume , paradoxical renal hepatic clearance increase observe early stage severe sepsis frequently observe ICU patient . Previous study report low aminoglycoside plasma concentration early phase therapy ICU patient . However , data subsequent dose aminoglycosides available . Therefore , address lack data , observational study perform describe proportion ICU patient achieve targeted aminoglycoside Cmax first subsequent aminoglycoside dos use conventional dosing regimen . Aminoglycoside agent give combination broad-spectrum antibiotic accord suspect pathogen local clinical practice . A once-daily dose regimen base French guideline use : ≥15 mg/kg amikacin ≥3 mg/kg gentamicin base actual weight admission . For obese patient , weight use dosing leave physician 's discretion.All aminoglycosides give 30-min i.v . infusion glucose 5 % solution . The timing Cmax sample 30 min end initial infusion . When subsequent dos aminoglycoside recommend part patient 's treatment plan , trough plasma concentration ( take 16-24 h post-infusion ) ( Cmin ) Cmax collect part routine practice.The target concentration amikacin gentamicin follow : amikacin , Cmax ≥60 mg/L Cmin &lt; 2.5 mg/L ; gentamicin , Cmax ≥30 mg/L Cmin &lt; 0.5 mg/L.The follow data collect : •demographic characteristic : age , sex , height , weight body mass index ( BMI ) ; •medical history , initial reason ICU admission Simplified Acute Physiology Score II ( SAPS II ) ICU admission ; •clinical parameter : urine output ; Sequential Organ Failure Assessment ( SOFA ) score Acute Kidney Injury Network ( AKIN ) score calculate daily initiation aminoglycoside therapy ; •presence renal replacement therapy ( RRT ) ; •co-prescription nephrotoxic agent ( e.g . glycopeptides , diuretic ) ; •biological parameter : serum creatinine concentration , hepaticf unction ( serum total bilirubin transaminase ) platelets daily measure routine practice ; •type infection anti-infective therapy microbiological culture collect . Amikacin gentamicin concentration measure use automate immunoassay ( Roche Diagnostics GmbH , Mannheim , Germany ) COBAS®C System .</detailed_description>
	<mesh_term>Cardiac Glycosides</mesh_term>
	<criteria>18 year indication aminogycoside therapy current infectious episode &lt; 18years allergy aminoglycosides patient guardianship</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>